Petros Pharmaceuticals, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Petros Pharmaceuticals, Inc. (PTPI) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $654.77 thousand as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2024-11-13
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $654.77K.
- 2024-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.37M.
- 2024-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.09M.
- 2023-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $800.03K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2024-09-30 | $654.77K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $1.37M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $2.09M 10-Q · filed 2024-05-15 |
| 2023-09-30 | $800.03K 10-Q · filed 2023-11-15 |
| 2023-06-30 | $1.62M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $2.45M 10-Q · filed 2023-05-15 |
| 2022-09-30 | $913.72K 10-Q/A · filed 2022-11-15 |
| 2022-06-30 | $3.08M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $4.63M 10-Q · filed 2022-05-16 |
| 2021-09-30 | $1.69M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $3.42M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $5.14M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |